[Will there soon be a sub-type specific treatment? New approaches to multiple sclerosis therapy].
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D003167:Complement Activation / Q000276:immunology; D000068717:Glatiramer Acetate; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D008134:Long-Term Care; D008264:Macrophages / Q000276:immunology; D009103:Multiple Sclerosis / Q000145:classification / Q000188:drug therapy* / Q000276:immunology; D009186:Myelin Sheath / Q000276:immunology; D010455:Peptides / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D000276:Adjuvants, Immunologic; D000305:Adrenal Cortex Hormones; D001323:Autoantibodies; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a